{"id":64331,"date":"2026-04-30T15:08:47","date_gmt":"2026-04-30T07:08:47","guid":{"rendered":"https:\/\/flcube.com\/?p=64331"},"modified":"2026-04-30T15:08:47","modified_gmt":"2026-04-30T07:08:47","slug":"hansoh-pharmaceuticals-b7-h3-adc-hs-20093-receives-china-btd-for-advanced-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64331","title":{"rendered":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that its investigational <strong>antibody-drug conjugate (ADC) HS-20093<\/strong> has received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>advanced castration-resistant prostate cancer (CRPC)<\/strong> in patients who have previously received <strong>novel endocrine therapy and paclitaxel-based chemotherapy<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HS-20093 \u2013 in-house developed B7-H3-targeted antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced castration-resistant prostate cancer (CRPC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Previously treated with novel endocrine therapy and paclitaxel-based chemotherapy<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Late-stage clinical development with expedited regulatory pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: <strong>B7-H3 (CD276)<\/strong> \u2013 immune checkpoint protein overexpressed in multiple solid tumors including prostate cancer<\/li>\n\n\n\n<li><strong>Technology Platform<\/strong>: <strong>Antibody-drug conjugate (ADC)<\/strong> combining tumor-targeting antibody with potent cytotoxic payload<\/li>\n\n\n\n<li><strong>Development Origin<\/strong>: <strong>In-house discovery and development<\/strong> by Hansoh&#8217;s proprietary biologics platform<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses critical unmet need in heavily pre-treated CRPC patients with limited remaining options<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Intravenous infusion (standard for ADC therapeutics)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-context-amp-market-need\">Clinical Context &amp; Market Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Population Size<\/strong><\/td><td>Advanced CRPC affects approximately 30,000-40,000 patients annually in China requiring third-line or later therapy<\/td><\/tr><tr><td><strong>Current Treatment Landscape<\/strong><\/td><td>Limited options after progression on endocrine therapy and taxane chemotherapy, including PARP inhibitors (for BRCA-mutated) and radioligand therapy<\/td><\/tr><tr><td><strong>Unmet Medical Need<\/strong><\/td><td>High demand for effective therapies in biomarker-agnostic CRPC population regardless of genetic alterations<\/td><\/tr><tr><td><strong>B7-H3 Expression Profile<\/strong><\/td><td>Broadly expressed in prostate cancer with limited expression in normal tissues, providing favorable therapeutic window<\/td><\/tr><tr><td><strong>Competitive Differentiation<\/strong><\/td><td>First B7-H3-targeted ADC to receive BTD in China for prostate cancer indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-commercial-outlook\">Strategic Implications &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Platform Validation<\/strong>: Success validates Hansoh&#8217;s internal ADC development capabilities and target selection strategy<\/li>\n\n\n\n<li><strong>Prostate Cancer Franchise<\/strong>: Establishes foothold in high-value oncology indication with significant commercial potential<\/li>\n\n\n\n<li><strong>Regulatory Acceleration<\/strong>: BTD status enables expedited review processes and potential priority approval pathways<\/li>\n\n\n\n<li><strong>Global Potential<\/strong>: Strong clinical data could support international partnerships or regulatory filings in other markets<\/li>\n\n\n\n<li><strong>Pipeline Catalyst<\/strong>: Positive momentum may accelerate development of other B7-H3-targeted assets in Hansoh&#8217;s pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory outcomes, and commercial potential for HS-20093. Actual results may differ due to risks including pivotal trial outcomes, regulatory decisions, competitive developments, and market dynamics in the prostate cancer therapeutic landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042904571_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026042904571_c.\"><\/object><a id=\"wp-block-file--media-925a552a-c3ae-4c2b-be48-0918eab2324b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042904571_c.pdf\">2026042904571_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042904571_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-925a552a-c3ae-4c2b-be48-0918eab2324b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,34,1182],"class_list":["post-64331","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-breakthrough-therapy","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical&#039;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China&#039;s National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.B7-H3 ADC prostate cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64331\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical&#039;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China&#039;s National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64331\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T07:08:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical&#8217;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer\",\"datePublished\":\"2026-04-30T07:08:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331\"},\"wordCount\":405,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Breakthrough therapy\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64331#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64331\",\"name\":\"Hansoh Pharmaceutical's B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T07:08:47+00:00\",\"description\":\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.B7-H3 ADC prostate cancer\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64331\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64331#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical&#8217;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical's B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.B7-H3 ADC prostate cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64331","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical's B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer","og_description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.","og_url":"https:\/\/flcube.com\/?p=64331","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T07:08:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64331#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64331"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer","datePublished":"2026-04-30T07:08:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64331"},"wordCount":405,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Breakthrough therapy","HKG: 3692"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64331#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64331","url":"https:\/\/flcube.com\/?p=64331","name":"Hansoh Pharmaceutical's B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T07:08:47+00:00","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093 has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for the treatment of advanced castration-resistant prostate cancer (CRPC) in patients who have previously received novel endocrine therapy and paclitaxel-based chemotherapy.B7-H3 ADC prostate cancer","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64331#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64331"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64331#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical&#8217;s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64331"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64331\/revisions"}],"predecessor-version":[{"id":64333,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64331\/revisions\/64333"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}